A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers. (Q51054715)

27 March 2018

title

A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers. (English)

1 reference

27 March 2018

1 reference

Jaemoon Koh

1

1 reference

27 March 2018

Heounjeong Go

2

1 reference

27 March 2018

Moon-Young Kim

3

1 reference

27 March 2018

Yoon Kyung Jeon

4

1 reference

27 March 2018

Jin-Haeng Chung

5

1 reference

27 March 2018

Doo Hyun Chung

6

1 reference

27 March 2018

publication date

6 October 2014

1 reference

27 March 2018

published in

Histopathology

1 reference

27 March 2018

volume

65

1 reference

27 March 2018

issue

6

1 reference

27 March 2018

page(s)

868-878

1 reference

27 March 2018

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

cites work

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

21 January 2018

1 reference

Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.

21 January 2018

1 reference

Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies.

21 January 2018

1 reference

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

21 January 2018

1 reference

Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.

21 January 2018

1 reference

Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.

21 January 2018

1 reference

Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category

21 January 2018

1 reference

Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.

21 January 2018

1 reference

Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice

21 January 2018

1 reference

A comparative study of machine-learning methods to predict the effects of single nucleotide polymorphisms on protein function.

21 January 2018

1 reference

Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.

21 January 2018

1 reference

Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype

21 January 2018

1 reference

p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma

21 January 2018

1 reference

p40: a p63 isoform useful for lung cancer diagnosis - a review of the physiological and pathological role of p63.

21 January 2018

1 reference

p40 (ΔNp63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: a review and comparative analysis.

21 January 2018

1 reference

P63 expression in lung carcinoma: a tissue microarray study of 408 cases

21 January 2018

1 reference

P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors

21 January 2018

1 reference

p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?

21 January 2018

1 reference

Immunhistochemistry by Means of Widely Agreed-Upon Markers (Cytokeratins 5/6 and 7, p63, Thyroid Transcription Factor-1, and Vimentin) on Small Biopsies of Non-small Cell Lung Cancer Effectively Parallels the Corresponding Profiling and Eventual Diag

21 January 2018

1 reference

ΔNp63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, Sparing-Material Approach

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/HIS.12507

1 reference

27 March 2018

1 reference

27 March 2018